Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Investig Clin Urol. 2023 Sep;64(5):457-465. doi: 10.4111/icu.20230065.
To compare renal function change by urinary diversion (UD) type (ileal conduit [IC] vs. neobladder [NB]) in patients with a single kidney who underwent radical cystectomy (RC) due to bladder cancer.
We evaluated the renal function change in 86 patients with a single kidney who underwent RC between January 1999 and August 2022. Renal function was assessed using serum creatinine, serum estimated glomerular filtration rate (eGFR), eGFR difference value (preoperative and follow-up values), and eGFR difference proportion (eGFR difference value/preoperative eGFR) at 1, 3, 6, 12, 24, 36, 48, and 60 months. In addition, multiple definitions of eGFR decline were evaluated: 10 points, 10%, and 20% decline in eGFR. Cox regression models were used to identify risk factors of eGFR decline-free, recurrence-free, overall, and cancer-specific survival rates.
A total of 54 patients (62.8%) underwent IC, whereas 32 (37.2%) underwent NB. Baseline characteristics were similar between the two groups except for age and body mass index. Renal functions over time by various methods did not differ significantly between the IC and NB groups. Furthermore, eGFR decline-free survival rate using different definitions was similar between the IC and NB groups. Overall survival, recurrence-free survival, and cancer-specific-free survival rates were not different between the IC and NB groups.
UD type (IC vs. NB) did not impact the renal function change of patients with a single kidney who underwent RC. Therefore, patients with a single kidney might be considered to be an indication of NB.
比较因膀胱癌行根治性膀胱切除术(RC)的单肾患者中不同尿流改道术(肠代膀胱[IC]与新膀胱[NB])对肾功能的影响。
我们评估了 1999 年 1 月至 2022 年 8 月期间 86 例因膀胱癌行 RC 且单肾的患者的肾功能变化。通过血清肌酐、血清估算肾小球滤过率(eGFR)、eGFR 差值(术前与随访值)以及 eGFR 差值比例(eGFR 差值/术前 eGFR)在术后 1、3、6、12、24、36、48 和 60 个月评估肾功能。此外,还评估了 eGFR 下降的多种定义:eGFR 下降 10 点、10%和 20%。使用 Cox 回归模型来确定 eGFR 无下降、无复发、总体和癌症特异性生存率的危险因素。
54 例(62.8%)患者行 IC,32 例(37.2%)行 NB。两组患者的基线特征除年龄和体重指数外,无显著差异。不同方法的肾功能随时间的变化在 IC 和 NB 两组之间无显著差异。此外,不同定义的 eGFR 无下降生存曲线相似。IC 和 NB 两组的总体生存、无复发生存和癌症特异性无生存无差异。
尿流改道术类型(IC 与 NB)对行 RC 的单肾患者的肾功能变化无影响。因此,单肾患者可能被认为是行 NB 的适应证。